Cure8 research brief
The study suggests that anti‑TNF treatment in IBD is associated with weaker and less cross‑reactive antibody and memory B‑cell responses after COVID‑19 booster vaccination, which may reduce durability of protection and supports consideration of ongoing booster strategies.
Patients with IBD on anti‑TNF biologics, clinicians managing immunosuppressed IBD patients, and researchers of vaccine immune responses
The study measured serum neutralizing antibodies, RBD‑specific IgG, and memory B cells at baseline, 1 month and 6 months after bivalent or monovalent booster vaccination in 27 IBD patients on intravenous anti‑TNF and 44 controls.
Patients mounted increases in antibodies and memory B cells after boosting but at lower levels and with fewer cells that recognized multiple viral subvariants. The authors interpret this as impaired immune memory in anti‑TNF‑treated patients and note support for annual boosters.
The article is a preprint/abstract-level report (Europe PMC entry) and not a peer‑reviewed journal publication here. It describes immunologic laboratory measures rather than clinical outcomes such as rates of breakthrough infection or severe disease.
Preprint/abstract-level report focused on immune laboratory measures (antibodies and memory B cells) with a small cohort; not evidence of clinical outcomes. Findings support existing recommendations for periodic booster vaccination but should be interpreted alongside peer-reviewed studies and clinical guidelines.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
